Johnson & Johnson pulls out of HIV phase III trial
Johnson & Johnson stopped the phase III trial of its global HIV vaccine trial after it found that the regimen was ineffective in.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Johnson & Johnson stopped the phase III trial of its global HIV vaccine trial after it found that the regimen was ineffective in.
India is bolstering its regulatory bodies to global standards to become a world leader in drug discovery and innovative medical devices, a minister.
Glenmark Pharmaceuticals, an Indian multinational firm, has introduced its heart failure drug in the country, according to a company statement.
Pharma major Lupin has received a ātentative approvalā, from the United States Food and Drug Administration (FDA), to market medicines used to treat.
The USFDA has granted Zydus Lifesciences Limited ātentative approvalā to market Levomilnacipran extended-release capsules in 20 mg, 40 mg, 80 mg, and 120.
Eiasi Co., a Japanese pharmaceutical company, has submitted a marketing authorization application for a drug, lacanemab, to treat Alzheimer's disease.
he current treatment of cortical malformations in the anterior parts of the brain, or cerebrum, in vertebrates by its surgical removal to cure.
China has provided the WHO with information about its outpatient clinics, hospitalizations, patients requiring emergency treatment and hospital deaths due to Coivd-19 infection,.
An artificial intelligence-powered machine can reduce the treatment time for stroke patients by 60 minutes and free up cliniciansā time.
The American Academy of Pediatrics has issued guidelines advising aggressive treatment of obesity in children as young as 12.